Acute Kidney Injury After Rapid Tirzepatide Dose Escalation: Warning Case Report

Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.

Almansour, Abdulelah H·The American journal of case reports·2025·Preliminary Evidencecase series
RPEP-09880Case seriesPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
case series
Evidence
Preliminary Evidence
Sample
N=very small
Participants
Single patient with multiple comorbidities who received accelerated tirzepatide dosing

What This Study Found

Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.

Key Numbers

Single patient case with multiple comorbidities. AKI developed after dose escalation faster than the recommended schedule.

How They Did This

Methodology detailed in publication.

Why This Research Matters

Relevant to expanding peptide-based therapeutic applications.

The Bigger Picture

Contributes to the growing evidence for peptide therapeutics.

What This Study Doesn't Tell Us

Limitations in publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to existing evidence?
  • ?Next research steps?

Trust & Context

Key Stat:
Key finding Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multip
Evidence Grade:
Based on study design in publication.
Study Age:
Published in 2025.
Original Title:
Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.
Published In:
The American journal of case reports, 26, e950781 (2025)
Database ID:
RPEP-09880

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.

How reliable?

Consult publication and healthcare provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09880·https://rethinkpeptides.com/research/RPEP-09880

APA

Almansour, Abdulelah H. (2025). Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.. The American journal of case reports, 26, e950781. https://doi.org/10.12659/AJCR.950781

MLA

Almansour, Abdulelah H. "Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.." The American journal of case reports, 2025. https://doi.org/10.12659/AJCR.950781

RethinkPeptides

RethinkPeptides Research Database. "Acute Kidney Injury After Accelerated Dosing of Tirzepatide ..." RPEP-09880. Retrieved from https://rethinkpeptides.com/research/almansour-2025-acute-kidney-injury-after

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.